Articles tagged with Interleukin Signaling
Researchers found that patients with major depressive disorder share immune abnormalities with inflammatory skin diseases, including atopic dermatitis. The study suggests targeting the Th2 pathway and interleukin-4 receptor alpha as potential therapeutic strategies for psychiatric illness.
Researchers have identified three distinct immunotypes in EPTB patients, revealing new insights into disease mechanisms. Additionally, gene expression-based biomarkers have been developed to reliably diagnose both pulmonary and extrapulmonary tuberculosis.
Researchers at Penn State College of Medicine discovered a new function of antibody-making B cells in response to flu infection. These cells produce a key signaling molecule called interleukin-1 beta, which is necessary for developing a robust immune response and forming optimal germinal centers.
Researchers found that HPV16 undermines the body's defenses by reprogramming immune cells surrounding tumors. Blocking IL-23 boosts experimental treatments for HPV to eliminate cancer cells.
A new study using a novel mouse strain expressing Halo-tagged SOCS1 reveals that the inhibitor needs to exceed a threshold level to suppress GM-CSF and IFN-gamma signaling. The findings emphasize SOCS1's crucial function in modulating cytokine signaling.
A Kobe University study finds that a new treatment for neuromyelitis optica spectrum disorder shifts the balance of immune cells, increasing anti-inflammatory signals. The discovery may enable clinicians to determine treatment effectiveness and move towards personalized medicine for autoimmune diseases.
A new murine model of dermatomyositis reveals the underlying immune system involvement in this highly progressive disease. The study identifies key components of the immune system responsible for disease development and suggests potential treatments targeting interleukin-6.
The Texas Heart Institute has been awarded $1.14 million by the NIH to develop a novel, first-in-class drug for treating atherosclerotic cardiovascular disease. The goal of this research is to target lingering inflammation in patients with cardiovascular disease.
Researchers found that IL-6 signaling in allergen-specific T cells was needed to suppress commitment to the harmful Th2 lineage. SOCS3 upregulation by IL-6 inhibits JAK/STAT internal signaling pathway, preventing Th2 cell priming.
A recent study found that heavy alcohol use changes signaling pathways in the brain, affecting cognitive functions like decision-making and impulse control. The mechanism involves the brain's immune system and the molecule interleukin 1β, which regulates inflammation and neurotransmitter release.
Scientists from Trinity College Dublin discovered that Interleukin-37 activates the immune system, contrary to earlier theories. This finding has significant implications for understanding and treating autoimmune disorders and inflammation.
Researchers discovered that infections improve the production and function of naïve T cells, the body's first line of defense against disease. This mechanism involves interleukin 7 and MHC molecules, which signal naïve T cells to stay alive and receive optimal metabolic signals.
Chaperones, molecular protein machines, ensure that proteins are built correctly. In the study, researchers found that chaperones retain one part of interleukin 23-alpha until it is incorporated into the complete complex, controlling its secretion and biosynthesis.